- Home
- USEA vs PLUR Comparison
USEA vs PLUR Comparison
Compare USEA & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USEA | PLUR |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | Greece | Israel |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7M | 25.5M |
| IPO Year | 2022 | 2001 |
Fundamental Metrics
Financial Performance| Metric | USEA | PLUR |
|---|---|---|
| Price | $2.71 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 44.3K | 29.8K |
| Earning Date | 05-21-2026 | 05-08-2026 |
| Dividend Yield | ★ 11.22% | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,336,000.00 |
| Revenue This Year | $5.55 | $97.38 |
| Revenue Next Year | $4.60 | $293.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $1.42 | $1.45 |
| 52 Week High | $2.82 | $5.68 |
Technical Indicators
Market Signals| Indicator | USEA | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 58.78 | 49.57 |
| Support Level | $2.48 | $1.56 |
| Resistance Level | $2.78 | $2.01 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 77.14 | 69.23 |
Price Performance
Historical ComparisonAbout USEA United Maritime Corporation
United Maritime Corp is an international shipping company currently specializing in world-wide seaborne transportation services. It currently operates a fleet of dry bulk vessels, comprising Panamax, Capesize and Kamsarmax vessels. Its vessels include Dukeship, Nisea, Cretansea, Chrisea, Synthesea, and Exelixsea.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.